Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute mye… Read more
Syros Pharmaceuticals Inc (SYRS) - Net Assets
Latest net assets as of September 2024: $-11.12 Million USD
Based on the latest financial reports, Syros Pharmaceuticals Inc (SYRS) has net assets worth $-11.12 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($85.00 Million) and total liabilities ($96.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.12 Million |
| % of Total Assets | -13.09% |
| Annual Growth Rate | -13.31% |
| 5-Year Change | -78.96% |
| 10-Year Change | N/A |
| Growth Volatility | 58.83 |
Syros Pharmaceuticals Inc - Net Assets Trend (2014–2023)
This chart illustrates how Syros Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Syros Pharmaceuticals Inc (2014–2023)
The table below shows the annual net assets of Syros Pharmaceuticals Inc from 2014 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $16.66 Million | -86.96% |
| 2022-12-31 | $127.74 Million | +49.89% |
| 2021-12-31 | $85.22 Million | -5.89% |
| 2020-12-31 | $90.55 Million | +14.36% |
| 2019-12-31 | $79.18 Million | +0.76% |
| 2018-12-31 | $78.59 Million | +20.30% |
| 2017-12-31 | $65.32 Million | -18.95% |
| 2016-12-31 | $80.60 Million | +136.72% |
| 2015-12-31 | $34.05 Million | -43.48% |
| 2014-12-31 | $60.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Syros Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 69911200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $26.00K | 0.16% |
| Other Components | $739.44 Million | 4437.90% |
| Total Equity | $16.66 Million | 100.00% |
Syros Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Syros Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lanbay Inc
PINK:LNBY
|
$330.16K |
|
Cingulate Inc. Warrants
NASDAQ:CINGW
|
$330.18K |
|
New Momentum Corporation
PINK:NNAX
|
$330.34K |
|
Grapefruit USA Inc
PINK:GPFT
|
$330.36K |
|
Fila Korea Ltd.
KQ:081660
|
$329.82K |
|
2G ENERGY - Dusseldorf Stock Exchang
DU:2GB
|
$329.66K |
|
MAROC LEASING
BC:MAROC-LEASING
|
$329.42K |
|
Eros Resources Corp
OTCQB:EROSF
|
$329.39K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Syros Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 127,736,000 to 16,661,999, a change of -111,074,001 (-87.0%).
- Net loss of 164,574,000 reduced equity.
- Dividend payments of 42,105,000 reduced retained earnings.
- Share repurchases of 257,000 reduced equity.
- New share issuances of 43,270,000 increased equity.
- Other comprehensive income decreased equity by 102,000.
- Other factors increased equity by 52,693,999.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-164.57 Million | -987.72% |
| Dividends Paid | $42.10 Million | -252.7% |
| Share Repurchases | $257.00K | -1.54% |
| Share Issuances | $43.27 Million | +259.69% |
| Other Comprehensive Income | $-102.00K | -0.61% |
| Other Changes | $52.69 Million | +316.25% |
| Total Change | $- | -86.96% |
Book Value vs Market Value Analysis
This analysis compares Syros Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $243.34 | $0.02 | x |
| 2015-12-31 | $137.54 | $0.02 | x |
| 2016-12-31 | $63.48 | $0.02 | x |
| 2017-12-31 | $25.71 | $0.02 | x |
| 2018-12-31 | $24.06 | $0.02 | x |
| 2019-12-31 | $19.69 | $0.02 | x |
| 2020-12-31 | $19.66 | $0.02 | x |
| 2021-12-31 | $13.63 | $0.02 | x |
| 2022-12-31 | $10.11 | $0.02 | x |
| 2023-12-31 | $0.59 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Syros Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -987.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1656.34%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 10.09x
- Recent ROE (-987.72%) is below the historical average (-165.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -22.30% | 0.00% | 0.00x | 1.02x | $-19.46 Million |
| 2015 | -87.57% | -9406.31% | 0.01x | 1.28x | $-33.22 Million |
| 2016 | -59.23% | -15060.88% | 0.00x | 1.13x | $-55.80 Million |
| 2017 | -82.68% | -4905.54% | 0.01x | 1.20x | $-60.54 Million |
| 2018 | -79.25% | -3038.00% | 0.02x | 1.36x | $-70.14 Million |
| 2019 | -95.27% | -3806.16% | 0.01x | 1.89x | $-83.36 Million |
| 2020 | -94.78% | -568.67% | 0.07x | 2.35x | $-94.89 Million |
| 2021 | -106.16% | -385.15% | 0.13x | 2.15x | $-98.99 Million |
| 2022 | -38.60% | -331.32% | 0.06x | 1.91x | $-62.07 Million |
| 2023 | -987.72% | -1656.34% | 0.06x | 10.09x | $-166.24 Million |
Industry Comparison
This section compares Syros Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Syros Pharmaceuticals Inc (SYRS) | $-11.12 Million | -22.30% | N/A | $329.84K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |